EYEPRIM™ is a sterile medical device designed to perform conjunctival impressions of the living eye. It enables further analysis of cells and biomarkers to help diagnose several ocular surface disorders, such as dry eye, allergies or infections.
The EYEPRIM™ device is based on an original idea, suggested by Christophe Baudouin, MD, PhD, Chairman of Department of Ophthalmology III at Quinze-Vingts Hospital and Research team leader at the Vision Institute, Team S12, Inserm-UPMC Research Center 968.
Why use EYEPRIM™ for conjunctival impressions?
The conjunctival impression technique allows the collection of cells from the conjunctiva in a nearly painless and non-invasive way, for the purpose of analyses (cytology, cytometry, PCR...) and diagnosis.
This technique is recommended by the TFOS (Tear Film & Ocular Surface Society) in the 2007 Report of the International Dry Eye Workshop.
EYEPRIM™ greatly facilitates the conjunctival impression technique, thus making it available for all practitioners. It is very much appreciated for the clinical studies follow-up thanks to its sampling reliability, high yield and very little training requirement.
It is used in several clinical studies in US and Europe.
EYEPRIM™ is a Class I (sterile) medical device according to the directive 93/42/CEE, CE 0051 (IMQ) and FDA exempted from Premarket Authorization Procedure according to Code of Federal regulation Title 21: 21CFR880.6025.
More information is available on the EYEPRIM™ website.
TEARPRIM™ is a sterile medical device designed to sample the tear film. It enables further analysis of tear components to help diagnose several ocular surface disorders, such as dry eye or allergies.
The TEARPRIM™ device was developed in close collaboration with Quinze-Vingts Hospital and ophthalmologists.
This new tear sampling device aims to replace the tedious, labor-intensive current sampling and the non-standardized techniques (capillary tube, Schirmer strip, etc…).
TEARPRIM™ allows the collection of a high quantity of tears in a nearly painless and minimally-invasive way.
TEARPRIM™ is a Class IIa (sterile) medical device according to the directive 93/42/CEE, CE 0051 (IMQ).
More information is available on the TEARPRIM™ website.
What is IONTOFOR-VET?
IONTOFOR-VET is a complete administration set that allows the veterinarians to use iontophoresis to deliver Riboflavin into the corneal stroma for the PACK-CXL procedure. It includes a corneal applicator, a vial of Ribovet (Riboflavin) and a vacuum syringe.
Why use IONTOFOR-VET for PACK-CXL?
PACK-CXL is a therapeutic procedure that uses photo-activated chromophores against the pathogens involved in infectious keratitis.
The penetration of the chromophores into the corneal stroma is conventionally achieved by corneal soaking with a Riboflavin solution for 30 minutes.
Studies have shown that Riboflavin penetration can be enhanced by iontophoresis, a procedure consisting in applying an electrical current to an ionisable substance to increase its mobility across a surface.
The administration set IONTOFOR-VET uses iontophoresis technology to improve PACK-CXL procedure by reducing the soaking phase from 30 minutes to 5 min without removing the epithelium.
IONTOFOR-VET must be used with the I-ON CXL current generator for veterinary use and an ultraviolet light emitting source for ophthalmic use (UV-A; 370nm).
IONTOFOR-VET is for veterinary use only.
More information is available on the IONTOFOR-VET website.
What is IONTOFOR-VET Electrode?
IONTOFOR-VET Electrode is an administration set that allows the veterinarians to use iontophoresis to deliver a large array of products into the corneal stroma. It includes a corneal applicator and a vacuum syringe.
What are the compatible products?
IONTOFOR-VET Electrode is compatible with the following products. The polarity indicates the appropriate cable to use with the I-ON CXL current generator.
IONTOFOR-VET Electrode must be used with the I-ON CXL current generator for veterinary use.
IONTOFOR-VET Electrode is for veterinary use only.
Our pipeline currently comprises two devices under development for the treatment of ocular surface disorders and retinal disorders.
Other devices are in early development and target diagnosis and treatment of ophthalmic diseases.
Apart from our proprietary devices pipeline, OPIA provides R&D services to medical device and pharmaceutical companies.